Gilead: Twice-yearly lenacapavir nearly doubles one-year PrEP persistence vs daily oral F/TDF

The persistence gap is the real headline here: adherence, not efficacy, has long been the weak link in oral PrEP, and a twice-yearly option that keeps most users on schedule reframes the delivery model rather than just the drug. It matters most for populations where daily pill-taking is hardest to sustain, and for payers weighing dosing frequency against cost. The single infection versus none is too small a sample to carry weight on its own. Worth watching is whether persistence holds outside trial conditions and how the injectable's logistics fit into existing PrEP channels.